title: Treatment for relapsed Hodgkin lymphoma: refinement of chemotherapy or targeted treatment?
abstract: The prognosis for those with relapsed Hodgkin lymphoma is poor. This evaluation is of two new approaches to the treatment of relapsed Hodgkin lymphoma. First, is a refinement of the chemotherapy for the relapsed condition, which showed that adding SHDCT (sequential high-dose chemotherapy of cyclophosphamine, uromitexane, granulocyte colony-stimulating factor, methotrexate, vincristine, etoposide) did not improve outcome. Second, is new targeted treatment for relapsed Hodgkin disease--brentuximab vedotin, which has an antitubulin agent (monomethylauristatin E) attached to a CD30-specific antibody. This agent gave promising results in a Phase I clinical trial in subjects with relapsed Hodgkin lymphoma. Brentuximab vedotin has produced good initial findings in the treatment of Hodgkin lymphoma and needs to be tested more widely.
authors.affiliation: Queensland University of Technology, Discipline of Medical Sciences, Faculty of Science and Technology, Brisbane, Australia. sheila.doggrell@qut.edu.au
authors.forename: Sheila A
authors.initials: SA
authors.lastname: Doggrell
mesh_terms: D002648:Child; D005047:Etoposide; D016179:Granulocyte Colony-Stimulating Factor; D006689:Hodgkin Disease; D006801:Humans; D017730:Ki-1 Antigen / Q000276:immunology; D008727:Methotrexate
chemical_list: D017730:Ki-1 Antigen; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D008727:Methotrexate